Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sanofi-aventis Enhances Its R&D Presence in China
November 17, 2008
- MTPC to Beef Up Domestic Marketing Force
November 17, 2008
- MOF Council Concerned about Little Progress in Use of Generics
November 17, 2008
- Effects of Amlodipine Generics within DSP's Expectations
November 17, 2008
- REGULATORY NEWS IN BRIEF
November 17, 2008
- Shionogi: Rosuvastatin, Doripenem Drive Business
November 17, 2008
- Home Monitoring Improves QOL of CRD Device Recipents
November 17, 2008
- Ono: Sales Down 7.5%, Long-Listed Products Accounting for over 90% of Total Sales
November 17, 2008
- Makers of Self-Monitoring Devices for Blood Glucose Required to Review Package Inserts
November 17, 2008
- Kowa to Make Livalo a Global Product
November 17, 2008
- Precautions for Cold Remedies Required for Children Less than 2 Years Old
November 17, 2008
- Diovan Ranked No. 1 for 2 Consecutive Months: Rep Track Survey
November 17, 2008
- Korosho Council to Promote Public Education on Cancer
November 17, 2008
- Adapalene to Promote Treatment of Acne in Japan: Prof. Kawashima
November 17, 2008
- Council to Collect Data from 200,000 Diabetic Nephropathy Patients
November 17, 2008
- 15 Doctors Certified as First Pharmaceutical Physicians
November 17, 2008
- Operating Profits of Top-Eight Domestic Companies Down Due to Aggressive Investments
November 17, 2008
- Sales of Irbesartan Total \2.3 Bil. in First 3 Months
November 17, 2008
- Price Settlement Rate Exceeds the Target of 70%
November 17, 2008
- Takeda Applies for Actos/Metformin Combination in Japan
November 10, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…